Loading
Drug development oncologist who directs the OHSU Knight Cancer Institute.
Shivaani Kummar is Director of the OHSU Knight Cancer Institute and Chief Scientific and Academic Officer of the Knight Cancer Group. A medical oncologist who previously led early clinical trials programmes at the US National Cancer Institute and Stanford, her research focuses on phase I trials, pharmacodynamic biomarkers and precision oncology.
| Title | Journal | Year |
|---|---|---|
| Tissue-Agnostic Drug Development: A New Path to Drug Approval | Cancer Discovery | 2021 |
| Compressing drug development timelines in oncology using phase '0' trials | Nature Reviews Cancer | 2007 |
| Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development | Cancers | 2024 |
Shares Cancer Discovery, Nature Reviews Cancer and the tags leadership, clinician-scientist.
Shares Cancers and the tags leadership, clinician-scientist.
Shares Cancers and the tags leadership, clinician-scientist.
Shares Cancer Discovery and the tags leadership, clinician-scientist.
Shares Nature Reviews Cancer and the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist, drug development.
Shares the tags leadership, clinician-scientist, precision oncology.
Shares the tags leadership, clinician-scientist, drug development.